Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603

Author(s): Yukihide Kanemitsu, MD1; Yasuhiro Shimizu, MD, PhD2; Junki Mizusawa, PhD1; Yoshitaka Inaba, MD, PhD2; Shunsuke Tsukamoto, MD, PhD1; Atsuo Takashima, MD, PhD1; Masayuki Ohue, MD, PhD3; Koji Komori, MD, PhD2; Akio Shiomi, MD4; Manabu Shiozawa, MD, PhD5; Yusuke Suwa, MD, PhD6; Takeshi Suto, MD7; Yusuke Kinugasa, MD, PhD8; Yasumasa Takii, MD9; Hiroyuki Bando, MD, PhD10; Takaya Kobatake, MD11; Masafumi Inomata, MD, PhD12; Yasuhiro Shimada, MD13; Hiroshi Katayama, MD1; Haruhiko Fukuda, MD1; JCOG Colorectal Cancer Study Group;
Source: DOI: 10.1200/JCO-25-01231
Original Article
Professional photo of Anjan J Patel, MD

Dr. Anjan Patel's Thoughts

The mature overall survival (OS) data from this Japanese randomized trial answer the question the initial publication left open, and the answer is no, adjuvant mFOLFOX6 after hepatectomy for resectable colorectal liver metastases does not improve overall survival (HR 1.07, P=.74), despite the previously reported DFS benefit. Five-year OS was numerically worse in the chemotherapy arm (73% vs 80%), though not significantly so. The disease-free survival (DFS) benefit was likely confounded by oxaliplatin-induced hepatic changes obscuring imaging and imbalances in post-recurrence therapy. Selection of patients and those with curable vs incurable intent surgery may have led to some bias in my opinion.

ABSTRACT

AbstractJCOG0603 demonstrated improved disease-free survival (DFS) with adjuvant mFOLFOX6 after hepatectomy compared with hepatectomy alone in colorectal liver-only metastasis (CRLM), but the overall survival (OS) data were immature. Here, we report OS after long-term follow-up. Eligible patients with colorectal adenocarcinoma and an unlimited number of liver metastases were randomized to adjuvant mFOLFOX6 or hepatectomy alone. DFS was the primary endpoint, and OS was a secondary endpoint. Between March 2007 and January 2019, 151 and 149 patients were randomized to adjuvant chemotherapy and hepatectomy alone, respectively. a median follow-up of 7.7 years for disease-free surviving patients, 54 (35.8%) and 51 (34.2%) patients had died in the respective arms, (hazard ratio [HR], 1.07 [95% CI, 0.73 to 1.57]). Five-year OS was 73.4% (95% CI, 65.5 to 79.7) and 80.1% (95% CI, 72.6 to 85.7) and 7-year OS was 69.4% (95% CI, 61.2 to 76.2) and 72.4% (95% CI, 64.2 to 79.1), respectively. One patient in the adjuvant chemotherapy arm possibly died of protocol treatment-related toxicity, and one in the hepatectomy-alone arm died of post-protocol treatment complications. Five-year DFS was respectively 49.7% (95% CI, 41.5 to 57.3) and 40.5% (95% CI, 32.5 to 48.3) in the adjuvant chemotherapy and hepatectomy-alone arms (HR, 0.72 [95% CI, 0.54 to 0.97]). Long-term OS did not differ with adjuvant mFOLFOX6 compared with hepatectomy alone in resectable CRLM. Adjuvant mFOLFOX6 may delay recurrence but did not improve long-term survival.

Author Affiliations

1National Cancer Center Hospital, Tokyo, Japan; 2Aichi Cancer Center Hospital, Nagoya, Japan; 3Osaka International Cancer Institute, Osaka, Japan; 4Shizuoka Cancer Center Hospital, Shizuoka, Japan; 5Kanagawa Cancer Center, Kanagawa, Japan; 6Yokohama City University Medical Center, Yokohama, Japan; 7Yamagata Prefectural Central Hospital, Yamagata, Japan; 8Institute of Science Tokyo, Tokyo, Japan; 9Niigata Cancer Center Hospital, Niigata, Japan; 10Ishikawa Prefectural Central Hospital, Kanazawa, Japan; 11National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; 12Oita University Faculty of Medicine, Yufu, Japan; 13Kochi Health Sciences Center, Kochi, Japan

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Colonoscopy Intervals and Colorectal Cancer Incidence after Adenoma Removal

This one could reshape post-polypectomy surveillance. In nearly 11,000 patients with high-risk adenomas, waiting 5 years instead of 3 for the first surveillance colonoscopy was noninferior for colorectal cancer incidence (under 1% in both arms), with no apparent shift toward later-stage disease and roughly half as many colonoscopies. The 3-year arm picked up more advanced adenomas (15% vs 11%), but that didn't translate into fewer or earlier cancers. Caveats: this is an interim analysis that only narrowly met noninferiority, and only about two-thirds of patients completed 5-year surveillance, so the 10-year data will be the real test before guidelines move.

Read More »

Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial

Encouraging phase I signal for this HER2-targeted Antibody-drug conjugate (ADC) in heavily pretreated GI cancers, 45% overall response rate (ORR) and 16.3mo median overall survival (OS) in HER2-positive gastric compares favorably with T-DXd benchmarks, and the 40.5% objective response rate (ORR) with 22.7mo OS in HER2-positive colorectal cancer (CRC) is notable. The 2% ILD rate looks meaningfully better than T-DXd’s reported range, which could be a real differentiator. Hematologic toxicity is substantial but manageable. Small China-only phase I, but worth watching closely as this advances.

Read More »

Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial

For high-risk patients with four or more colorectal liver metastases, adjuvant hepatic arterial infusion oxaliplatin roughly doubled hepatic recurrence-free survival versus standard IV chemotherapy (25 vs. 12 months), with recurrence-free survival (RFS) benefit as well. Overall survival (OS) didn't reach significance but the absolute difference and 5-year OS of 62% versus 47% suggest a real effect worth confirming in phase III. Toxicity was higher in the hepatic arterial infusion (HAI) arm but manageable with no treatment-related deaths. Generalizability remains the challenge, these needs specialized centers with HAI expertise, but worth keeping in mind for your highest-risk resected liver met patients.

Read More »

Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer: The ORCHESTRA Randomized Clinical Trial

Open-label, phase 3 clinical trial, 382 patients were randomized to receive chemotherapy alone or chemotherapy plus tumor debulking. The overall survival rates were not statistically different, with a median overall survival in the chemotherapy alone group of 27.5 m vs 30.0 m in the chemotherapy plus tumor debulking group hence tumor debulking added to palliative systemic chemotherapy did not result in significantly improved survival compared with chemotherapy alone in patients with multiorgan metastatic colorectal cancer.

Read More »
Load More